Question special

Greetings! My name is Abraar Karan and I'm an MPH candidate at Harvard/ recent medical graduate from UCLA. One area that has always been of interest is the potential for pharmaceutical innovation in the global health sector. Many have discussed this in terms of the potential market that exists among developing economies, especially poorer populations that are afflicted specifically with diseases (such as Neglected Tropical Diseases) that are not substantial problems in the USA and other wealthier economies. Given the lack of a financial incentive from a purely market based view, how do we incentivize pharma innovation in this sector? Furthermore, how do we advocate for more fair pricing of existing drugs for these vulnerable communities?